New Delhi, – As India sees a recent uptick in COVID-19 cases, concerns are naturally rising. However, experts reiterate a crucial message: Coronavirus was never truly “gone,” and the latest variants, while warranting attention, are generally considered mild, akin to seasonal influenza.

What is the New Variant?

The recent rise in cases in India has been linked to new sub-variants like NB.1.8.1, LF.7, and JN.1, all part of the evolving Omicron lineage. Most notably, the KP.2 variant, a descendant of JN.1, has been gaining traction globally and has been detected in India, with a significant presence in states like Maharashtra, West Bengal, and Gujarat. This variant is part of a group colloquially termed “FLiRT” variants due to specific mutations in their spike protein.

Was Corona Gone?

The notion that “corona was gone” is a common misconception. While the intensity of the pandemic has significantly reduced from its peaks, and the World Health Organization (WHO) ended the Public Health Emergency of International Concern (PHEIC) for COVID-19 in May 2023, the virus (SARS-CoV-2) has continued to circulate and evolve. It has transitioned from a pandemic phase to an endemic one, meaning it is consistently present within the population, much like influenza.

No Need to Panic, But Be Prepared

Medical experts emphasize that the latest variants, including KP.2, are largely associated with mild symptoms, often resembling a common cold or viral fever. These symptoms typically include:

• Fever (often low-grade with JN.1)
• Cough
• Sore throat
• Fatigue
• Headache
• Runny or blocked nose
• Muscle aches
• Digestive issues like nausea, loss of appetite, stomach discomfort, and diarrhea (more prominent with JN.1)

However, it’s crucial to acknowledge that while the general severity is mild, these variants can still pose a risk, particularly to individuals with chronic diseases, the elderly, and those who are immunocompromised. For these vulnerable groups, vigilance and adherence to preventive measures remain paramount.

Progress in Vaccine Improvements and New Vaccines

Vaccine development continues to adapt to the evolving virus. Manufacturers like Moderna and Pfizer-BioNTech have updated their COVID-19 vaccines to target the prevailing variants. For instance, the 2024-2025 formulas for both Moderna’s Spikevax and Pfizer-BioNTech’s Comirnaty are formulated to protect against the KP.2 strain. Novavax has also introduced an updated recombinant protein-based vaccine.

These updated vaccines aim to elicit robust neutralizing antibody responses against the circulating JN.1-derived variants, including KP.2. While vaccination does not entirely prevent infection, it significantly reduces the risk of severe illness, hospitalization, and death, even against new variants.

Conclusion: Stay Informed, Not Alarmed

Based on current research and expert opinions, there is no need for widespread panic or worry regarding the latest surge in COVID-19 cases and the emergence of new variants like KP.2. The virus has become endemic, and its latest strains are generally milder.

However, a responsible approach is still necessary. This includes:

• Staying informed about local case trends and public health advisories.
• Practicing good hand hygiene.
• Considering mask-wearing in crowded or indoor settings, especially for vulnerable individuals.
• Staying home if unwell.
• Consulting a doctor if symptoms worsen, particularly for those with underlying health conditions.
• Keeping vaccinations up to date, including booster doses as recommended by health authorities, as they remain the best defense against severe outcomes.

Just as with the seasonal flu, living with COVID-19 means ongoing adaptation and responsible public health practices, rather than a return to the widespread alarm of earlier pandemic phases.